Newly emerging therapies targeting viral-related lymphomas

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

Gamma-(γ)-herpes virus lymphomas comprise a heterogenous group of B-cell and T-cell neoplasms most commonly associated with Epstein-Barr virus and rarely human herpes virus-8 infection. Adult T-cell leukemia/ lymphoma (ATLL) is a unique disease entity caused by the human T-cell lymphotrophic virus, type 1 (HTLV-I), the only retrovirus known to cause cancer in humans. Viral lymphomas behave aggressively and disproportionally affect immunocompromised individuals and those living in underdeveloped regions. These diseases are often difficult to treat with conventional approaches. Despite recent advancements using cytotoxic, lymphoma-specific, and adoptive therapies, the long-term outcome of patients with γ-herpesvirus lymphomas occurring in severely immunocompromised patients and ATLL continues to be poor. Lytic-inducing therapies targeting NF-κB, and viral and tumor cell epigenetic mechanisms afford the advantage of exploiting the intrinsic presence of oncogenic viruses to eradicate infected tumor cells. In this review, viral-related lymphomas and newly emerging clinical approaches targeting viral latency are discussed.

Original languageEnglish (US)
Pages (from-to)416-426
Number of pages11
JournalCurrent oncology reports
Volume13
Issue number5
DOIs
StatePublished - Oct 2011

Keywords

  • Adult T-cell lymphoma
  • Adult Tcell leukemia
  • AIDS-related lymphomas
  • EBV
  • Epstein-Barr virus
  • Gamma herpesvirus
  • HDAC inhibitors
  • HHV-8
  • HIV
  • HTLV-I
  • Human herpes virus-8
  • Human immunodeficiency virus
  • Human T-cell lymphotrophic virus
  • KSHV
  • Lymphoma
  • Lytic therapies
  • NF-κB
  • Nuclear factor kappa B
  • Oncology
  • Plasmablastic lymphoma
  • Primary effusion lymphoma
  • Type 1 human T-cell leukemia virus
  • Viral latency
  • Viral lymphomas

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Newly emerging therapies targeting viral-related lymphomas'. Together they form a unique fingerprint.

  • Cite this